Study Demonstrated Significant Efficacy and No
Serious Adverse Events
PHOENIX, May 18, 2023
/PRNewswire/ -- Creative Medical Technology Holdings, Inc.
("Creative Medical Technology" or the "Company") (NASDAQ:
CELZ), a biotechnology company focused on a regenerative
approach to immunotherapy, endocrinology, urology, gynecology, and
orthopedics, today announced positive top line pilot study results
for the StemSpine® procedure using AlloStem™
to treat chronic lower back pain. The data demonstrated
significant efficacy and no serious adverse events using the
StemSpine® ultrasound guided non-surgical procedure for
treating chronic lower back pain.
The StemSpine® procedure using AlloStem™
resulted in a greater than 90% reduction in narcotic usage, greater
than 80% reduction in pain score, and greater than 50% reduction in
the Oswestry Score in the treated patients. No patients
required re-dosage or surgical intervention at the primary end
point of six months and there were no safety related concerns.
StemSpine® using AlloStem™ is a
patented procedure that utilizes an "off the shelf, ready-to-use"
universal and proprietary allogenic (donor) cell developed by the
Company and trademarked as AlloStem™. The patent issued
to StemSpine® includes both the use of autologous (from
the patient) and allogenic (universal donor) cells. In
February 2023, the Company reported
positive three-year follow-up data for its StemSpine®
pilot study using autologous cells to treat chronic lower back
pain.
"To our knowledge, this pilot study is the first to demonstrate
safety and clinical efficacy of injecting AlloStem™ in
areas surrounding the disc, thereby potentially repairing,
remodeling, and improving the blood supply around the disc and
lower back area," said Timothy Warbington, President, and CEO
of the Company. "We believe that the results of this pilot
study using donor cells validate our prior work in the field in
which we used the StemSpine® procedure to treat chronic
lower back pain using a patient's own bone marrow harvested
cells. In evolving the application of our technology, we
believe the StemSpine® procedure using
AlloStem™ can expand treatment options for millions of
Americans who suffer from chronic lower back pain by providing
access to our universal donor cells."
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology
company dedicated to the advancement of identifying and translating
novel biological therapeutics in the fields of immunotherapy,
endocrinology, urology, gynecology, and orthopedics and is traded
on NASDAQ under the ticker symbol CELZ. For further information
about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at
www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-positive-top-line-study-results-for-chronic-lower-back-pain-utilizing-its-stemspine-procedure-using-allostem-allogenic-cell-line-301827652.html
SOURCE Creative Medical Technology Holdings, Inc.